MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AIMI made $26K in revenue. -$3,284K in net income. Net profit margin of -12630.77%.

Income Overview

Revenue
$26K
Net Income
-$3,284K
Net Profit Margin
-12630.77%
EPS
$1.57
Unit: Thousand (K) dollars
Revenue Breakdown
    • Clinical treatment programs - us

Income Statement
2025-09-30
2025-06-30
2025-03-31
Total revenues
26 25 16
Production costs
68 10 10
Research and development
607 1,174 1,080
General and administrative
1,798 1,487 2,545
Total costs and expenses
2,473 2,671 3,635
Operating loss
-2,447 -2,646 -3,619
Gain (loss) on investments
-1 -9 27
Interest and other income
3,052 10 11
Interest expense and other finance costs
148 149 124
Issuance cost
433 --
Loss on issuance of warrants
-3,977 0 -
Change in fair value of warrants
-670 --
Net loss
-3,284 -2,794 -3,705
Basic EPS
1.57 -3.68 -0.05
Diluted EPS
1.57 -3.68 -0.05
Basic Average Shares
2,093,446 759,289 70,329,869
Diluted Average Shares
2,093,446 759,289 70,329,869
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$3,284K Interest and other income$3,052K Change in fair value ofwarrants-$670K Clinical treatmentprograms - us$26K Loss on issuance ofwarrants-$3,977K Operating loss-$2,447K Total revenues$26K Issuance cost$433K Interest expense andother finance costs$148K Gain (loss) oninvestments-$1K Total costs andexpenses$2,473K General andadministrative$1,798K Research and development$607K Production costs$68K

AIM ImmunoTech Inc. (AIMI)

AIM ImmunoTech Inc. (AIMI)